The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: Statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis

Trials

Volumn 18, Issue 1, 2017, Pages

  Graham, Catriona ^a   Lewis, Steff ^b   Forbes, John ^c   Mead, Gillian ^b   Hackett, Maree L ^d   Hankey, Graeme J ^e   Gommans, John ^f   Nguyen, Huy Thang ^g   Lundström, Erik ^h   Isaksson, Eva ^h   Näsman, Per ⁱ   Rudberg, Ann Sofie ^h   Dennis, Martin ^b  

^a Queen's Medical Research Institute   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF LIMERICK   (Ireland)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Hawke's Bay District Health Board   (New Zealand)

^g People's Hospital 115   (Viet Nam)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Antidepressants; Depression; Fluoxetine; Haemorrhagic stroke; Ischaemic stroke; Recovery; SSRI

Indexed keywords

FLUOXETINE;

ACUTE CORONARY SYNDROME; ALGORITHM; ARTICLE; AUTOMUTILATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; COGNITION; DEATH; DEPRESSION; DRUG EFFECT; FALLING; FRACTURE; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPONATREMIA; MEDICATION COMPLIANCE; META ANALYSIS; MOOD; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANKIN SCALE; RECURRENT DISEASE; SEIZURE; SHORT FORM 36; SIDE EFFECT; SUICIDE ATTEMPT; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; FLUOXETINE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 85039552548     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-2385-6     Document Type: Article

References (30)

1. Mead G, Hackett ML, Lundström E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;20:369.
2. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-7.
3. Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005;330:843.
4. Counsell C, Dennis M, McDowall M, Warlow C. Predicting outcome after acute stroke: development and validation of new models. Stroke. 2002;33:1041-7.
5. Brott TG, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-70.
6. Bruno A, Shah N, Lin C, Close B, Hess D, Davis K, et al. Improving modified Rankin scale assessment with a simplified questionnaire. Stroke. 2010;41:1048-50.
7. Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, et al. Simplified modified Rankin Scale Questionnaire: reproducibility over the telephone and validation with quality of life. Stroke. 2011;42:2276-9.
8. Dennis M, Mead G, Doubal F, Graham C. Determining the modified Rankin score after stroke by postal and telephone questionnaires. Stroke. 2012;43(3):851-3.
9. Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ. The Stroke Impact Scale Version 2.0: evaluation of reliability, validity and sensitivity to change. Stroke. 1999;30:2131-40.
10. Duncan P, Reker D, Kwon S, Lai SM, Studenski S, Perera S, et al. Measuring stroke impact with the stroke impact scale: telephone versus mail administration in veterans with stroke. Med Care. 2005;43:507-15.
11. Kwon S, Duncan P, Studenski S, Perera S, Lai SM, Reker D. Measuring stroke impact with SIS: construct validity of SIS telephone administration. Qual Life Res. 2006;15:367-76.
12. Mead GE, Lynch J, Greig CA, Young A, Lewis SJ, Sharpe M. Evaluation of Fatigue scales in stroke. Stroke. 2007;38:2090-5.
13. Mead GE, Graham C, Dorman P, Bruins SK, Lewis SC, Dennis MS, et al. Fatigue after Stroke: Baseline Predictors and Influence on Survival. Analysis of Data from UK Patients Recruited in the International Stroke Trial. PLoS ONE. 2011;6:e16988.
14. Ware JE, Kosinski M, Dewney JE. How to score version 2 of the SF36 Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.
15. de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry. 2003;18:318-24.
16. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-9.
17. Berwick DM, Murphy JM, Goldman PA, Ware Jr JE, Barsky AJ, Weinstein MC. Performance of a five-item mental health screening test. Med Care. 1991;29:169-76.
18. Williams LS, Brizendine EJ, Plue L, Bakas T, Tu W, Hendrie H, et al. Performance of the PHQ-9 as a screening tool for depression after stroke. Stroke. 2005;36:635-8.
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
20. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L). Qual Life Res. 2011;20:1727-36.
21. Devlin N, Shah K, Feng Y, Brendan Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5 L value set for England. London: Office of Health Economics Research Paper; 2016.
22. Altman DG. Comparability of randomised groups. Statistician. 1985;34:125-36.
23. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke. 2007;38:1911-5.
24. Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated March 2011]. 2008. http://training.cochrane.org/handbook ]. Accessed 16th Dec 2017. http://training.cochrane.org/handbook.
25. Gabrio A, Mason A, Baio G. Handling missing data in within-trial cost-effectiveness analysis: a review with future guidelines. PharmacoEconomics Open. 2017;1:79-97.
26. Baio G, Berardi A, Heath A. Bayesian cost-effectiveness analysis with the R package BCEA. New York: Springer; 2016.
27. Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A. 2016;113(27):7353-60.
28. Bruins Slot K, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008;336:376-9.
29. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284-92.
30. Mead GE, Hankey GJ, Kutlubaev MA, Lee R, Bailey M, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke. Cochrane Database Syst Rev. 2011;11:CD009286.